Resmetirom (Rezdiffra) is used to treat nonalcoholic steatohepatitis (NASH) in adults with moderate to advanced liver scarring (fibrosis) but not with cirrhosis of the liver. It is a tablet taken once daily that is used along with diet and exercise.
Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of non cirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). [1]
Resmetirom is used together with diet and exercise to treat non-alcoholic steatohepatitis with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
Resmetirom is used for treatment of patients with nonalcoholic steatohepatitis (NASH; liver inflammation and damage caused by buildup of fat in the liver). Resmetirom is in a class of medications called thyroid hormone receptor (THR)-beta agonists.
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in...
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with ...
Rezdiffra (resmetirom) is commonly used to treat a specific liver disease called nonalcoholic steatohepatitis (NASH) in people who have scarring in their liver, also called fibrosis.
Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy.
Rezdiffra (resmetirom) is an FDA-approved oral medication used in adults to treat nonalcoholic steatohepatitis (NASH) with liver scarring without cirrhosis. It's the first of its kind to treat this condition, and you only need to take it once a day.